Related Experiment Video

Updated: May 26, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Targeting AKT protein kinase in gastric cancer

Khaldoun Almhanna1, Jonathan Strosberg, Mokenge Malafa

  • 1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Anticancer Research
|December 27, 2011
PubMed

Insights

Gastric cancer remains a deadly disease with poor survival rates. Targeting the AKT pathway shows promise in overcoming chemotherapy resistance and improving treatment outcomes for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gastric cancer is a leading cause of cancer death globally, with persistently low 5-year survival rates.
  • Targeted therapies have shown limited success, except for trastuzumab, despite extensive research.
  • Aberrant activation of Protein Kinase B (AKT) signaling is common in gastric cancer, contributing to survival and drug resistance.

Purpose of the Study:

  • To review current knowledge on AKT signaling in gastric cancer pathogenesis.
  • To explore the therapeutic potential of targeting the PI3K/AKT pathway in gastric cancer.

Main Methods:

  • Review of existing literature on AKT signaling and gastric cancer.
  • Analysis of pre-clinical data on PI3K/AKT pathway inhibitors in combination with chemotherapy.
  • Discussion of ongoing clinical development of AKT-targeted drugs.

Main Results:

  • The PI3K/AKT pathway plays a crucial role in gastric cancer cell survival and resistance to chemotherapy.
  • Combining PI3K/AKT pathway inhibitors with chemotherapy has demonstrated efficacy in preclinical gastric cancer models.
  • Development of novel AKT-specific inhibitors is advancing for clinical application.

Conclusions:

  • Targeting the AKT pathway represents a promising therapeutic strategy for gastric cancer.
  • Overcoming chemotherapy resistance through AKT inhibition could significantly improve patient outcomes.
  • Further clinical investigation of AKT-targeted therapies is warranted for gastric cancer treatment.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...